There needs to be a national dialogue on how can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want, said Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
There needs to be a national dialogue on how can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want, said Dr Robert Dubois, MD, PhD, chief science officer and executive vice president, National Pharmaceutical Council.
Transcript (slightly modified)
How will Going Below the Surface address the question of how well do we spend when it comes to healthcare? How will this help give an understanding to what’s driving healthcare spending?
We believe there is a national dialogue that needs to be occur, and a national dialogue that’s quite different than the 1 we’ve had in the past. For decades, we’ve had finger pointing exercises: “This is too expensive, this is causing the rise in expenditures, and if we’d only solve this problem, we’d have it resolved.”
The reality is, it’s an extensive and a difficult dialogue. Going Below the Surface initiative is really to do that, and to being to have those really tough questions talked about, looking at the costs, not just of drugs or hospitals, but also of devices and seeing specialists rather than primary care doctors or the lack of focus on social determinants. It’s really having that broad dialogue, and to not just look at the costs and pointing those fingers, but rather looking at the costs and benefits, and trying to very carefully say: “What would be best? How can we reach a point where our dollars are used wisely, patients get what they need, and we all get the innovation that we want.”
The Going Below the Surface initiative is really an opportunity to talk and reach that end of the journey.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More